IP Library Granted Patent US 11,441,150
Granted Patent B2
US 11,441,150 · App. 15/110,696 · Granted Sep 13, 2022

CPMV enhancer elements

Inventors: Pierre-Olivier Lavoie (Quebec, CA); Marc-Andre D'Aoust (Quebec, CA)
Assignee: Medicago Inc.
C12N15/8216C12N7/045C12N15/8251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,441,150
App. No.
15/110,696
Granted
Sep 13, 2022
Kind
B2
Abstract

An expression enhancer comprising a CPMV 5′UTR nucleotide sequence consisting of X nucleotides (CMPVX), where X=160, 155, 150, or 114 of SEQ ID NO:1, or consisting of a nucleotide sequence comprising from about 80% to 100% sequence similarity with CMPVX, where X=160, 155, 150, or 114 of SEQ ID NO:1 SEQ ID NO:1 is provided. The expression enhancer may further comprise a stuffer sequence fused to the 3′ end of the 5′UTR nucleotide sequence (CMPVX+, where X=160, 155, 150, or 114 of SEQ ID NO:1). The stuffer sequence may comprise one or more plant kozak sequences. Plants comprising the expression enhancer and methods using the expression enhancer are also described.

Claims (14)

1. A nucleic acid molecule comprising:

a first portion consisting of nucleotides 1-160 of SEQ ID NO:1 having a substitution of G1 15A, and

a second portion encoding a heterologous protein of interest, the second portion operatively linked to and fused immediately to the 3′ end of the first portion,

wherein transient expression of the nucleic acid molecule in a Nicotiana benthamiana plant increases a yield of the heterologous protein of interest, compared to transient expression of a comparative nucleic acid molecule comprising a corresponding first portion consisting of SEQ ID NO:4 in a comparative plant.

2. A plant expression system comprising the nucleic acid molecule of claim 1 or a vector comprising the nucleic acid molecule of claim 1 .

3. The plant expression system of claim 2 , wherein the nucleic acid molecule or vector further comprises a comovirus 3′ UTR.

4. The plant expression system of claim 2 , wherein the heterologous protein of interest is a viral protein or an antibody.

5. The plant expression system of claim 4 , wherein the viral protein is an influenza hemagglutinin selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and influenza type B hemagglutinin.

6. A method of producing a protein of interest in a plant or in a portion of a plant comprising, introducing into the plant or in the portion of a plant the plant expression system of claim 2 , and incubating the plant or the portion of a plant under conditions that permit expression of the heterologous protein of interest.

7. A plant or portion of a plant transiently transfected or stably transformed with the plant expression system of claim 2 .

8. The nucleic acid molecule of claim 1 , wherein the heterologous protein of interest is a viral protein or an antibody.

9. The nucleic acid molecule of claim 8 , wherein the viral protein is an influenza hemagglutinin selected from the group consisting of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and influenza type B hemagglutinin.

10. The plant expression system of claim 2 , further comprising a second nucleic acid molecule, the second nucleic acid molecule comprising a nucleotide sequence encoding a suppressor of silencing.

11. The plant expression system of claim 10 wherein the suppressor of silencing is selected from the group HcPro and p19 suppressor of silencing.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2024
From: MEDICAGO INC.
To: ARAMIS BIOTECHNOLOGIES INC.
Reel/Frame 069383/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: COUTURE, MANON; D'AOUST, MARC-ANDRE; VEZINA, LOUIS-PHILIPPE
To: MEDICAGO INC.
Reel/Frame 039294/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2016
From: LAVOIE, PIERRE-OLIVIER; D'AOUST, MARC-ANDRE
To: MEDICAGO INC.
Reel/Frame 039294/0258 →
Priority Claims (1)
CA PCT/CA2014/050326 · Mar 28, 2014 · national
Continuity (3)
Continuation In Part PCTCA2014050326 · Mar 28, 2014
Provisional Application 61925852 · Jan 10, 2014
Related Publication 20170029832A1 · Feb 2, 2017